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Objective: Pandemicfluhas changed theepidemiologyofpneumonia, thuschallenging thepredic-
tion of etiology and outcome.We analyze the risk factors to predict influenza A/H1N1 infection in
patients with pneumonia, and the impact of this etiology on mortality during a pandemic period.
Differences between pneumonia with or without A/H1N1 coinfection are described.
Methods: Retrospective observational study in 364 consecutive patients hospitalized with pneu-
monia during the A/H1N1 pandemic flu, AprileDecember 2009.
Results: 294 patients (80.5%) had A/H1N1() pneumonia, 47 (13.2%) A/H1N1(þ) pneumonia, and
23 (6.3%) coinfection. Mortality during hospitalization was 24/294 (8.2%), 8/47 (16.7%), 2/23
(8.7%) respectively. A regression logistic analysis (Area under curve, AUC 0.81) to predict
A/H1N1(þ) pneumonia identified four independent variables: age < 60 years (Odds ratio, OR
5.9), multilobar infiltrates (OR 7.7), C-reactive protein (CRP) < 10 mg/dL (OR 2.8), and
leukopenia < 5000/mm3 (OR 3.4). Risk factors for in-hospital mortality in the whole group were
A/H1N1 (þ) etiology and LDH > 600 IU/L (OR 4.1) when adjusting for PSI, and hypoxemia (OR
4.2) when adjusting for CURB 65 (AUC 0.81). Heart disease (OR 27.4) and LDH > 600 IU/L (OR
10.5) were risk factors for in-hospital mortality in A/H1N1(þ) patients (AUC 0.81)
Conclusion: Leukopenia, multilobar infiltrates, CRP<10 mg/dl and age < 60 years were indepen-
dently associatedwith A/H1N1(þ) etiology. Pandemic A/H1N1(þ) increasedmortality pneumonia.
Heart disease and LDH > 600 were independently associated with mortality in A/H1N1(þ) pneu-
monia.
ª 2011 Elsevier Ltd. All rights reserved.he Network of Centers for Biomedical Research on Respiratory Disease (CIBERES). CIBERES is an
tute (ISCIII).
Neumologı´a, Hospital Universitario y Polite´cnico La Fe, Bulevar Sur s/n, 46026 Valencia, Spain.
Reyes).
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Risk factors of A/H1N1 pneumonia and mortality 1405Introduction the Intensive Care Unit (ICU), with or without influenzaPneumonia is a severe infection with high morbidity and
mortality worldwide. The emergence of a novel influenza
virus A/H1N1, with a high degree of human transmission,
has changed the epidemiology, clinical pattern and prog-
nosis of pneumonia. During the A/H1N1 pandemic influenza
an increased incidence of pneumonia has been reported
and, thus, both primary viral and mixed etiology (Influenza
plus Streptococcus pneumoniae and Staphylococcus aureus)
pneumonia have been described.1e5 Clinical course,
severity of disease and outcome differ among these three
clinical pneumonia scenarios.
The clinical diagnosis of pneumonia, irrespective of
bacteriaor virusetiology, is basedonsignsand symptomsalong
with analytical results and the finding of a new infiltrate in
radiograph. Traditionally, signs and symptoms have been
considered highly unspecific to predict causal microorganisms
in pneumonia, so they are not usually taken in account for
selecting empirical treatment in current guidelines.6e8
Nevertheless, the pandemic influenza has showed a different
epidemiological pattern,3,9e13 and the incidence and impact
of coinfection with bacteria is not completely known. An
adequate treatment selection, both in bacterial14e16 and in A/
H1N1(þ) pneumonia,17,18 is key because it has been proved to
be an important protective factor against mortality. In fact,
the importance of initiating early empiric treatment in order
to improve prognosis is an important task in hospitalized
patients with severe pneumonia.19
The biological marker C-reactive protein (CRP) has been
evaluated as a diagnostic or prognostic tool in lower respira-
tory tract infections and pneumonia.20e24 Our hypothesis is
that, CRP levels added to other clinical and/or analytical
parameters might be helpful to predict the etiology of pneu-
monia during pandemic flu. We consider that estimating the
pretest probability of viral etiology is useful for clinicians in
order to prescribe a combination therapy (antibiotic and
antiviral), or to select the main candidates for performing
viral microbiological studies. This information might be valu-
able to maintain high suspicion in next successive waves.
Recently, the association of CRP>10 mg/dl with severe
outcomes in A/H1N1 pandemic influenza, independently of
pneumonia, has beendemonstrated.25However, the behavior
of CRP as a prognostic biomarker in pneumonia is not well
known during an epidemic flu wave.
The aim of our study was to identify risk factors to
predict influenza A/H1N1 etiology in pneumonia. As
a secondary aim, we evaluated the impact of the A/H1N1
etiology on pneumonia mortality. Furthermore, we aimed
to describe differences between the presence and absence
of bacterial coinfection in those patients with A/H1N1
pneumonia.Material and methodsStudy subjects and design
This study was conducted in a Spanish tertiary hospital.
Data were collected retrospectively on all patients with
pneumonia admitted to the Pneumology department or toA/H1N1 infection, according to case definitions developed
by the World Health Organization.26 The study period lasted
from April 26th to December 30th 2009.
Pneumonia was defined as symptoms and/or signs of
lower respiratory tract infection (e.g. temperature>38 C,
productive cough, chest pain, shortness of breath, crackles
on auscultation) and the presence of a new infiltrate on
chest radiograph. Immunosuppressed patients were
included in the study during the pandemic period. We
excluded patients hospitalized in the previous 15 days.
A/H1N1(þ) pneumonia was defined as pneumonia plus
a positive real-time reverse transcription-polymerase chain
reaction (RT-PCR), bacterial coinfection was defined as
A/H1N1(þ) etiology plus a proven bacterial diagnosis.
The study was approved by the Ethics Committee of the
University Hospital La Fe, Valencia (Spain). The data were
coded to keep anonymity of the patients; informed consent
was waived because of the non-interventional study design.Methods
Data collection
The protocol for data collection included: age, sex,
smoking and alcohol consumption, vaccination status in
2008e2009, pregnancy, comorbid conditions (chronic
obstructive pulmonary disease (COPD), asthma, heart,
liver, neurological, renal, or neoplastic diseases, diabetes
mellitus, immunosuppression). Obesity was defined as
a body mass index (kg/m2) >30. We recorded clinical signs,
symptoms, analytical data and radiological findings in the
first 24 h. Collected symptoms and signs were headache,
cough, expectoration, chest pain, dyspnea, confusion,
diarrhea, fever>38 C, heart rate, respiratory rate and
blood pressure. The analytical data included leukocyte,
neutrophil and lymphocyte counts, sodium, potassium,
serum creatinine, glucose, blood urea nitrogen (BUN),
creatin kinase (CK), lactate dehydrogenase (LDH), CRP, and
arterial blood gas analysis. Radiological findings were also
documented: multilobar (2) or bilateral infiltrates, and
pleural effusion. The Pneumonia Severity Index (PSI)27 and
CURB 65 28 were calculated in all patients.
At diagnosis, antibiotic and antiviral therapy with osel-
tamivir was prescribed in all patients. Antibiotics were
prescribed according to the Spanish guidelines, Sociedad
Espan˜ola de Neumologı´a y Cirugı´a Tora´cica (SEPAR).6,7
Oseltamivir was subsequently discontinued in patients
with RT-PCR negative results.
Microbiologic studies
Several samples were obtained for microbiological studies:
1) Nasopharyngeal swab specimens to detect influenza
virus, nZ 364 (100%); 2) blood cultures, nZ 289 (79.2%); 3)
serum for paired serology (at admission and after 4 weeks)
for Chlamydophila pneumoniae, Mycoplasma pneumoniae,
Coxiella burnetii and Legionella pneumophila, n Z 91
(24.9%); 4) urine to detect antigens of Legionella pneu-
mophila serogroup 1 and Streptococcus pneumoniae using
an immunochromatographic test, n Z 350 (95.9%); and 5)
respiratory samples, by valid sputum, n Z 164 (44.9%),
(representative sputum originating from the lower
1406 S. Reyes et al.respiratory tract was defined as that containing 25 gran-
ulocytes and 10 epithelial cells per low power field (total
magnification: x100), by flexible fiberoptic bronchoscopy,
n Z 27 (7.4%), or pleural liquid, n Z 14 (3.8%), were
obtained according to the clinical judgment of the physi-
cian in charge.
Microbiological diagnostic criteria
A/H1N1 influenza virus infection was diagnosed by RT-PCR,
in accordance with published guidelines from the U.S.
Centers for Disease Control and Prevention (CDC)29. The
bacterial etiology was established by: 1) positive urinary
antigens of Streptococcus pneumoniae or Legionella pneu-
mophila; 2) blood cultures or pleural fluid yielding
a bacterial pathogen; 3) bacterial growth >105cfu/ml in
bronchoaspirate, >104cfu/ml in bronchoalveolar lavage
fluid, or if a valid sputum sample yielded one or more
predominant bacterial strains; 4) serology criteria, i.e.,
a fourfold increase in IgG titers for Chlamydophila pneu-
moniae (>1:512), Chlamydophila psittaci (>1:64), Legion-
ella pneumophila (>1:128), Coxiella burnetii (>1:80) or
a single increased IgM titer for Chlamydophila pneumoniae
(>1:32), Coxiella burnetii (>1:80), and Mycoplasma pneu-
moniae (any titer).
Coinfection was defined as present bacterial criteria
along with positive RT-PCR results.Analysis
Data analysis was performed using SPSS 15.0 software.
Categorical variables results are expressed as counts
(percentage) and continuous variables as medians with
interquartile range (IQR). We classified the group into three
subsets: A/H1N1() pneumonia, A/H1N1(þ) pneumonia,
and coinfection. The in-hospital mortality analyses
were performed in the whole group and in the subset of
A/H1N1(þ) pneumonia.
Univariate analysis was performed using chi square test
for categorical variables and ManneWhitney U and Krustall-
Wallis ANOVA tests for continuous variables. Four multi-
variate stepwise logistic regression analyses were per-
formed: the first model to predict A/H1N1 (þ) etiology, two
models to predict mortality in the whole cohort - one
adjusting for PSI and another adjusting for CURB 65-, and
the last model to predict in-mortality of A/H1N1 (þ)
pneumonia. Independent variables included in the four
models were those found significant in univariate analyses
and those considered clinically relevant such as pregnancy,
obesity, comorbidities and hypoxemia.
In the first model, influenza A/H1N1(þ) etiology was the
dependent variable and as independent variables we
included age, cough, diarrhea, respiratory rate, BUN,
multilobar infiltrates, pleural effusion, leukopenia, CRP,
LDH and CK. In the second (adjusting for PSI) and third
model (adjusting for CURB 65), in-mortality in the whole
group was the dependent variable and the independent
variables were multilobar infiltrates, leukopenia, CRP, LDH,
CK, and A/H1N1(þ) etiology. In the fourth model, in-
mortality of A/H1N1(þ) pneumonia was the dependent
variable and the independent variables were multilobar
infiltrates, leukopenia, CRP, LDH, CK.The independent variables were dichotomized as
follows: age, using the median (<60: yes/no), PSI was
categorized as high (Fine risk classes IVeV) or low risk
(classes IeIII), CURB 65 was categorized as high risk 3 or
low 2, leukopenia (<5000/mm3: yes/no), hypoxemia
(PO2<60 mmHg:yes/no), CRP (<10 mg/dl: yes/no), CK
(90 IU/L: yes/no), LDH (600 IU/L: yes/no).
To calculate the predictive value of the model, we
calculated the area under the ROC curve of the multivar-
iate logistic regression analysis to predict infection by
influenza A/H1N1 and mortality. Hosmer-Lemeshow and
goodness of fit tests were performed for each model.30
Results
Study population
The study comprised 364 patients: 294 (80.5%) A/H1N1()
pneumonia patients, 47 (13.2%) A/H1N1(þ) pneumonia, and
23 (6.3%) A/H1N1(þ) and bacterial coinfection. Etiology in
patients with A/H1N1() pneumonia was as follows: 197
(66.8%) unknown, 50 (16.9%) Streptococcus pneumoniae, 14
(4.7%) Legionella pneumophila, 3 (1%) Pseudomonas sp, 5
(1.7%) Escherichia coli, 5 (1.7%) Staphylococcus aureus, 6
(2.0%) Mycoplasma pneumoniae, 3 (1.0%) Haemophilus
influenzae, 2 (0.7%) Streptococcus sp, and others. In the
coinfected group, bacterial etiology was: 13 (56.5%)
Streptococcus pneumoniae, 4 (17.4%) Pseudomona aerugi-
nosa, 2 (8.7%) Staphylococcus aureus, and others.
Thirty four patients (9.3%) required ICU admission: 17
(5.4%) of those with A/H1N1() pneumonia, 13 (27.1%) of
those with A/H1N1(þ) pneumonia, and 4 (17.4%) among
those with coinfection.
Univariate analysis
Demographics, comorbidity, initial severity
The main demographic characteristics, comorbidity and
initial severity measured by PSI are shown in Table 1. We
found more pregnant women and patients <60 years, and
less comorbid conditions (diabetes, liver, heart
or neoplastic diseases and neurological disorders) in the
A/H1N1(þ) pneumonia group. In patients with A/H1N1()
pneumonia a higher age was found (p:0.0001), as well as
higher scores of PSI (p:0.0001).
Twenty-three patients with A/H1N1(þ) pneumonia had
coinfection, and comparing to those with A/H1N1 infection
alone there were more cases with COPD (p:0.006) and
immunosupression (p:0.058).
Clinical, analytical and radiological findings
Headache (p:0.03) and cough (p:0.002) were more frequent
in A/H1N1(þ) pneumonia. No differences were found con-
cerning other symptoms and physical signs. Median time
from the onset of illness to hospital admission was lower in
patients with A/H1N1() than in those with A/H1N1(þ)
pneumonia (3 vs 6 days, p:0.0001).
Analytical parameters and radiological findings in the
three subsets are shown in Table 2. In patients with
A/H1N1(þ) pneumonia, irrespective of coinfection, we found
significantly higher levels of LDH (p:0.004) and CK (p:0.007)
Table 1 Demographics, comorbidity and initial severity according to etiology.
A/H1N1() pneumonia A/H1N1(þ) pneumonia p valuec p valued
Coinfection Non coinfection
No. of patientsb 294 (80.5) 23 (6.3) 47 (13.2)
Demographics
Age in yearsa 65(45e79) 47(26e60) 42(32e50) 0.0001 0.5
Male genderb 166(56.5) 13(56.5) 21(43.8) 0.2 0.3
Pregnancyb 4(1.4) 1(4.3) 4(8.3) 0.01 0.7
Comorbid conditionsb
Obesity 53(18.0) 6(26.1) 7(14.6) 0.4 0.2
Diabetes 71(24.1) 2 (8.7) 5(10.5) 0.03 0.8
Liver disease 21(7.1) 0 0 0.07
Heart disease 64(21.8) 4(17.4) 4(8.3) 0.09 0.3
Renal disease 22(7.5) 2(8.7) 0 0.1 0.04
Neoplasm 15(5.1) 0 1(2.1) 0.3 0.5
Neurological disorder 42(14.3) 0 0 0.003
Asthma 26(8.8) 2(8.7) 7(14.6) 0.4 0.4
COPD 37(12.6) 5(21.7) 1(2.1) 0.03 0.006
Immunosupression 26(8.8) 5(21.7) 3(6.3) 0.09 0.058
Initial severityb
PSI IeIII/IVeV 184(62.6)/110(37.4) 18 (78.3)/5(21.7) 44(93.8)/3(6.3) 0.0001 0.058
CURB 65  2/3 209(71.1)/85(28.9) 21(91.3)/2(8.7) 45(93.8/3(6.3) 0.001 0.7
a Data expressed in median (25th to 75th interquartile range).
b Data expressed in n(%).
c Statistical analysis of the three subsets (Krustall-Wallis ANOVA test for continuous variables and chi square test for categorical
variables).
d Statistical analysis of A/H1N1(þ) patients with vs. without coinfection.
Abbreviations: COPD, chronic obstructive pulmonary disease; PSI, Pneumonia Severity Index.
Table 2 Laboratory and radiological findings according to etiology.
A/H1N1() pneumonia A/H1N1(þ) pneumonia p valuec p valued
Coinfection Non coinfection
No. of patientsb 294 (80.5) 23 (6.3) 47 (13.2)
White blood cells/103a
Leukocytes 11.5(8.4e16.3) 8.3(6.2e13.0) 7.4(5.0e11.0) 0.0001 0.2
Neutrophils 9.5(6.2e14.1) 6.8(5.0e12.1) 6.3(3.4e9.3) 0.0001 0.1
Lymphocytes 1.0(0.7e1.5) 0.9(0.7e1.3) 1.1(0.7e1.4) 0.6 0.4
Leukocytes <5000b 13(4.4) 3(13.0) 12(25.0) 0.0001 0.2
Biochemistrya
Creatinine (mg/dL) 1.0(0.8e1.3) 0.9(0.7e1.8) 0.8(0.7e0.9) 0.02 0.1
BUN (mg/dL) 18(14e29) 17(12e30) 12(9e18) 0.004 0.03
LDH (IU/L) 397(334e517) 436(386e963) 470(373e971) 0.004 0.8
CK (IU/L) 68(43e114) 91(47e178) 95(58e289) 0.007 0.5
CRP (mg/dL) 15.9(6.3e28.7) 19.1(11.9e26.0) 9.1(4.8e19.2) 0.03 0.01
Hypoxemiab 90(30.8) 8(34.8) 19(39.6) 0.4 0.2
Radiographic findingsb
Multilobar infiltrates 70(23.9) 10(43.5) 28(58.3) 0.0001 0.2
Bilateral infiltrates 36(12.3) 10(43.5) 19(39.6) 0.0001 0.8
Pleural effusion 42(14.3) 1(4.3) 3(6.3) 0.1 0.7
a Data expressed in median (25th to 75th interquartile range).
b Data expressed in n(%).
c Statistical analysis of the three subsets (Krustall-Wallis ANOVA test for continuous variables and chi square test for categorical
variables).
d Statistical analysis of A/H1N1(þ) patients with vs. without coinfection.
Abbreviations: BUN, Urea nitrogen; LDH, lactate dehydrogenase; CK, creatin kinase; CRP, C-reactive protein.
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CRP was significantly lower in A/H1N1(þ) pneumonia without
bacterial coinfection compared to the other two subsets.
Using theCRPselectedcut-off valueof10mg/dlwefoundthat
20/23 (87.0%) of patients with coinfection had higher levels
compared to 20/47 (42.6%) of those with A/H1N1(þ) pneu-
monia alone, (p:0.0001). Multilobar and/or bilateral infil-
trates were more frequent in A/H1N1(þ) pneumonia
(p:0.0001), while pleural effusion was more common,
although not significantly, in A/H1N1() pneumonia (p:0.1).
Mortality
Thirty four patients died during hospitalization: 24 (8.2%) of
those with A/H1N1() pneumonia, 8 (16.7%) of those with
A/H1N1(þ) pneumonia and 2 (8.7%) of thosewith coinfection.
In Table 3 we show data of age, comorbid conditions,
analytical parameters and radiological findings of patients
who died. In A/H1N1() pneumonia, in-hospital mortality
was higher in elderly patients, in those with neurological
disorders and higher scores of PSI. In the subset of A/H1N1(þ)
pneumonia patients, we found lower age, higher LDH and
lower scores of PSI.
In Table 4, medians of CRP and LDH in the three subsets are
shown. Although CRP and LDHwere higher in thosewho died in
A/H1N1(þ), the difference did not reach statistical signifi-
cance, probably due to a beta error. Significantly higher levels
of LDHwere found in thosewhodied in A/H1N1() pneumonia.
Multivariate analyses
Four logistic regression analyses were performed: one to
predict influenza A/H1N1(þ) pneumonia, two to predictTable 3 Differences of mortality of A/H1N1() and A/H1N1(þ)
Mortality
A/H1N1() n Z 24/295 (8.1%
Demographics and comorbidities
Age in yearsa 79(71e88)
Neurological disorder b 9(37.5)
Asthmab 0
Laboratory findingsa
Leucocytes 12.9(10.3e17.5)
Hypoxemia 20(83.3)
BUN 32(21e49)
CK 100(49e432)
LDH 517(374e634)
CRP 15.9(9.0e28.7)
Prognostic scalesb
PSI IeIII/IVeV 3(12.5)/21(87.5)
CURB 65  2/3 7(29.2)/17(70.8)
Radiographic findingsb
Multilobar infiltrates 11(45.8)
Bilateral infiltrates 6(25.0)
PaO2, Oxigen arterial pressure; BUN, Urea nitrogen; CK, creatin kin
Pneumonia severity index.
a Data expressed in median (25th to 75th interquartile range).
b Data expressed in n(%).in-hospital mortality in the whole group, and one to predict
in-mortality in A/H1N1 (þ) pneumonia. The first mathe-
matical model selected the following variables to predict
influenza A/H1N1 infection (Table 5): age, multilobar
infiltrates, CRP and leukopenia. The AUC of the model was
0.81 (0.75e0.88).
The mathematical models to predict in-hospital
mortality are also depicted in Table 5. In the whole
group, the independent variables that were associated with
higher mortality were: A/H1N1 etiology, high severity,
LDH>600 IU/L (adjusting for PSI) and hypoxemia (adjusting
for CURB 65) (AUC 0.85; 0.79e0.90). The risk factors of
mortality in A/H1N1(þ) pneumonia were the presence of
heart disease and LDH>600 IU/L (AUC 0.81; 0.65e0.97).
The Chi-squared goodness-of-fit analysis demonstrated
the adequacy of the models (p > 0.05).Discussion
The most important findings of our study can be summa-
rized as follows. 1) associated factors of A/H1N1(þ)
etiology in pneumonia were age<60, multilobar infiltrates,
CRP<10 mg/dL, and leukopenia < 5000/mm3; 2) Coin-
fection appeared in 33% of A/H1N1 pneumonia, mainly in
COPD and immunosupressed patients; 3) pneumonia
mortality during pandemic A/H1N1 was independently
associated with A/H1N1(þ) etiology and LDH>600 IU/L
(when adjusting for PSI) or hypoxemia (when adjusting for
CURB 65); and 4) mortality risk factors for A/H1N1(þ)
pneumonia were heart disease and LDH>600 UI/L.
The appearance of the new influenza pandemic A/H1N1
has challenged even more our capacity to predict bacterial
or viral etiology in pneumonia. Clinicians must maintainpneumonia.
) A/H1N1(þ) n Z 10/70 (14.3%) p value
44(23e75) 0.009
0 0.02
2(20.0) 0.02
9.0(7.3e13.4) 0.2
7(70) 0.3
22(14e40) 0.1
135(93e289) 0.4
840(456e1138) 0.04
19.0(5.8e25.6) 0.9
7(70.0)/3(30.0) 0.001
8(80.0)/2(20.0) 0.007
8(80.0) 0.06
6(60.0) 0.05
ase; LDH, lactate dehydrogenase; CRP, C-reactive protein; PSI,
Table 4 Results of CRP and LDH according to mortality and etiology of pneumonia.
Total n Z 364 Mortality n Z 34 (9.3%) Non-mortality n Z 331 (90.7%) p
CRP (mg/dL)
A/H1N1() 15.8(6.4e28.6) 19.0(5.8e25.6) 11.8(5.5e21.1) 0.4
A/H1N1(þ) 9.1(4.4e19.3) 15.5(4.8e23.6) 8.3(4.3e19.1) 0.5
A/H1N1(þ) and bacteria 19.1(11.9e26.0) 22.6(19.1e26.0) 17.3(11.9e25.5) 0.5
LDH (IU/L)
A/H1N1() 397(334e517) 517(374e634) 392(332e501) 0.03
A/H1N1(þ) 475(368e971) 758(403e1830) 470(356e912) 0.2
A/H1N1(þ) and bacteria 436(386e963) 989(840e1138) 408(386e548) 0.2
Data expressed in median (25th to 75th interquartile range).
CRP, C-reactive protein; LDH, lactate dehydrogenase.
Risk factors of A/H1N1 pneumonia and mortality 1409a high suspicion level of viral etiology, as rapid diagnostic
tests and/or PCR are not available in all hospitals. There-
fore, recommended empiric treatment in hospitalized
pneumonia during pandemic A/H1N1 included an antibiotic
along with antivirals, a combination due to the difficulty of
presuming viral or bacterial etiology.31 The potential role of
biomarkers in this new scenario merits attention in order to
improve diagnosis and prognosis.
In our study, we found demographic and comorbid
conditions in A/H1N1(þ) pneumonia similar to prior pub-
lications.9e11,13,32,33 Regarding coinfection, patients were
older than those with A/H1N1(þ) alone and had more often
comorbid conditions such as COPD or immunosupression, as
reported by Estenssoro et al.4. Martin-Loeches et al,3 didn’t
find differences in comorbidities, although they reported
more frequent coinfection in elderly patients and in those
with higher initial severity. Analytical parameters showed
higher levels of LDH and CK and lower counts of leukocytes
in A/H1N1(þ) than in bacterial pneumonia. Interestingly, the
clinical pattern of coinfection shares characteristics of both
etiologies. Leukocyte and neutrophyl counts showed higher
levels in bacterial etiology, intermediate in coinfection and
lower in A/H1N1(þ) pneumonia. CRP also behavedTable 5 Multivariate logistic regression analyses to predict
mortality (in the whole group and in the subset of A/H1N1 pneum
A/H1N1(þ) etiologya Mortality in pne
adjusted PSIb
OR (95% CI) p value OR(95% CI)
Age < 60 years 5.9(2.1e16.3) 0.001
Heart disease
Multilobar infiltrates 7.7(3.1e19.4) 0.0001
CRP<10 mg/dL 2.8(1.1e6.8) 0.02
Leukocyte <5000/mm3 3.4(1.1e11.2) 0.04
Hypoxemia
LDH > 600 IU/L 4.1(1.5e11.2)
A/H1N1(þ) 5.3(1.6e18.1)
PSI IVeV/IeIII 17.2(4.8e61.0)
CURB 65  2/3
CRP, C-reactive protein; LDH, lactate dehydrogenase; PSI, Pneumonia
a Prediction of A/H1N1 (þ) infection, AUC: 0.81(0.75e0.88).
b Prediction of mortality in the whole group, adjusted PSI AUC: 0.8
c Prediction of mortality in A/H1N1(þ) pneumonia, AUC: 0.81 (0.65differently in viral and bacterial etiology: lower in
A/H1N1(þ) than in bacterial pneumonia, while it was higher
in coinfection. Radiological findings showed pleural effusion
more often in bacterial etiology (14 vs. 6%) while multilobar
infiltrates were predominant in A/H1N1(þ) pneumonia,
irrespective of coinfection.
The multivariate statistical analysis to predict A/H1N1(þ)
pneumonia selected CRP below 10 mg/dL (OR 2.8) as an
independent variable, along with age<60 (OR 5.9) multilobar
infiltrates (OR 7.7), and leukopenia (OR 3.4). The AUC of the
model to predict viral etiology was 0.81, quite a high diag-
nostic accuracy. If age is not included in the model, assuming
that epidemiology of A/H1N1 in successive waves could
change, the remaining three risk factors retained a high
diagnostic value (data not shown), with an AUC of 0.80
(0.74e0.86). Moreover, CRP >10 mg/dL in A/H1N1(þ) pneu-
monia should alert the clinician about coinfection with
bacteria. Ingram et al,34 in critically ill A/H1N1(þ) patients,
reported that bacterial infection or coinfection with A/H1N1,
wasunlikelywhenCRPis low.CRP isavailable inmosthospitals
and has the potential to aid for suspecting viral pneumonia,
and to initiate a combination of antiviralþ antibiotics in order
to avoid a delayed treatment.influenza A/H1N1(þ) pneumonia and to predict in-hospital
onia).
umonia Mortality in A/H1N1(þ)c
adjusted CURB-65b
p value OR(95% CI) p value OR(95% CI) p value
27.4(2.4e311.1) 0.007
4.2(1.4e12.7) 0.009
0.005 10.6(1.1e96.7) 0.03
0.007 5.7(1.6e20.2) 0.006
0.0001
8.9(2.6e30.4.8) 0.0001
severity index.
5(0.79e0.90) and adjusted CURB-65 AUC: 0.81(0.73e0.88).
e0.97).
1410 S. Reyes et al.In A/H1N1(þ) pneumonia, the most common prognostic
scales, PSI and CURB 65, proved useless to predict mortality,
as previously reported.35,36 Concerning mortality, CRP was
higher although without reaching statistical significance.
That finding is opposite to its confirmed usefulness in
community-acquired pneumonia to predict complications
and mortality.24,37,38 That is, during pandemic flu, its inter-
pretation as a biomarker for mortality should be more
cautious. However, in influenza A/H1N1 patients (71%
without pneumonia and including a pediatric population) the
threshold of CRP>10 mg/dl has been associated with severe
outcomes and mortality.25 On the other hand, we found that
LDH behaved as a better biomarker than CRP to predict
mortality,9,32,39 keeping its independent association in the
multivariate analysis. Although several publications have
reported higher levels of CK in those patients who died,9,40
we did not find this association, such as Kumar et al.12
Mortality of pneumonia during pandemic flu showed
interesting findings. We confirmed that, after adjusting for
PSI or CURB 65, A/H1N1 etiology was an independent factor
for mortality. Our findings confirmed a higher mortality in
influenza A/H1N1 pneumonia compared to A/H1N1()
pneumonia.11,13,32 Multilobar infiltrates and hypoxemia
were also independent risk factors for mortality.41
The independent predictors of mortality in A/H1N1(þ)
pneumonia were the presence of heart disease (OR 27.4) and
LDH>600 IU/L (OR10.5). Cardiovascular involvement inacute
influenza infection can occur through a myocardium direct
effect or through exacerbation of previous disease.42,43
Interestingly, mortality in coinfection was lower than in
A/H1N1 pneumonia alone, although the low number of
cases precludes us from reaching firm conclusions. In
a study of necropsies it was reported that a bacteria was
found in 30% of A/H1N1 infection,44 and it was more
frequent in pediatric patients.40,45
One limitation of our study is its retrospective design,
although we used a standardized data collection form used
in pneumonia studies in our hospital. Furthermore, we
included all consecutive patients during the pandemic
period and all of them were investigated for A/H1N1. Other
limitations are that the rate of coinfection may have been
underestimated and that the subsets of A/H1N1(þ) pneu-
monia and coinfection are small.
In conclusion, some findings such as leukopenia, multi-
lobar infiltrates along with CRP<10 with have a good diag-
nostic value to predict A/H1N1 pneumonia. A high level of
CRP should alert about coinfection with bacteria in A/H1N1
pneumonia. During pandemic flu, CRP could lose its predic-
tive value for mortality whereas a raised LDH behaved as
a better biomarker of poor outcome in pneumonia.Conflict of interest
None declared.References
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